PCOS & Metabolic Risks

Kasi Subbiah
3 days ago
13 min read

From insulin resistance to Mounjaro (tirzepatide)

An evidence-based, patient-friendly guide to weight, insulin resistance, metformin and modern weight-management medicines.

Evidence reviewed: 31 August 2026

PCOS is not simply an ovary problem

The ovaries may have made it into the name, but PCOS is rather fond of involving the whole body.

For some women, the most troublesome part of PCOS is excess facial hair or acne. For others, it is irregular periods or difficulty becoming pregnant. This page is for the group whose main concern is metabolic health: weight gain, difficulty losing weight, insulin resistance, prediabetes or type 2 diabetes, high blood pressure, abnormal cholesterol, fatty liver risk or sleep apnoea.

These problems often overlap—but they are not identical. The right treatment depends on what is actually present, what matters most to you, whether pregnancy is possible or planned, and which treatment you can use safely and sustain.

The short version: There is no single “PCOS diet” and no compulsory PCOS body size. Healthy habits help even without weight loss. Metformin remains useful for glucose and insulin-related problems. Modern weight-management medicines can produce much greater weight loss when clinically appropriate. Tirzepatide (Mounjaro) is especially effective for obesity, and early PCOS-specific data are encouraging—but definitive trials showing that it directly treats PCOS itself are not yet available.

First, what exactly are we trying to treat?

Before choosing a tablet, injection or meal plan, it helps to identify the target.

Possible Target	Useful Questions
Insulin resistance or diabetes risk	Is glucose normal, in the prediabetes range, or in the diabetes range? Is there a strong family history or previous gestational diabetes?
Higher weight or central weight gain	Is weight affecting health, mobility, sleep, fertility or quality of life? Does the person actually want weight-management treatment?
Blood pressure or cholesterol	Are these persistently raised, and what is the person’s overall cardiovascular risk?
Sleep apnoea	Is there loud snoring, unrefreshing sleep, morning headache or marked daytime sleepiness?
Fatty liver risk	Are liver tests abnormal, or are diabetes and other metabolic risk factors present?
Pregnancy plans	Is pregnancy being attempted now, later, or not at all? This changes which medicines are safe.

The 2023 International PCOS Guideline recommends checking glucose status at diagnosis and then every one to three years according to risk. A 75-g oral glucose tolerance test (OGTT) is the most accurate test in PCOS; HbA1c or fasting glucose can be used when an OGTT is not practical, but they may miss some cases. Cholesterol should be checked at diagnosis, and blood pressure should be measured at least annually.

Importantly, metabolic screening is relevant whatever your weight. A slim waistcoat does not make insulin resistance hand in its resignation letter.

Why does PCOS affect metabolism?

The insulin–ovary loop

Insulin is the hormone that helps glucose move from the bloodstream into cells for use or storage. In insulin resistance, muscle, liver and fat cells respond less efficiently. The pancreas compensates by producing more insulin.

That higher insulin level can:

• encourage the ovaries to make more androgens;

• reduce the liver’s production of sex hormone-binding globulin, leaving more testosterone biologically available;

• promote energy storage and make appetite regulation harder in some people; and

• contribute over time to prediabetes, type 2 diabetes and an unfavourable cholesterol pattern.

Androgens and central fat accumulation may then worsen insulin resistance. This can become a biological feedback loop—not a character defect wearing a lab coat.

Not everyone with PCOS has obesity, and not everyone with obesity has PCOS. Weight is neither the cause of every case nor a moral scorecard. Genetics, ovarian biology, insulin signalling, sleep, medicines, environment and life circumstances all contribute.

The foundation: habits that improve health, not punishment disguised as healthcare

Lifestyle support is recommended for everyone with PCOS because it can improve central fat distribution, fitness, blood pressure, lipids, glucose and wellbeing. These benefits can occur even when the scales barely move.

Food: there is no single winning “PCOS diet”

No particular diet composition has proved superior for every woman with PCOS. The best pattern is nutritionally sound, culturally acceptable, affordable and realistic enough to survive a busy Tuesday.

A practical starting point is:

• include a source of protein at each main meal;

• favour vegetables, pulses, fruit and other fibre-rich foods;

• choose minimally processed carbohydrates more often and combine them with protein or healthy fats;

• reduce sugary drinks and foods that are easy to eat in large quantities without much fullness;

• use a meal pattern that reduces chaotic hunger; and

• if weight loss is desired, create a modest energy deficit without making food the full-time villain of the story.

Low-carbohydrate, Mediterranean-style, lower-glycaemic-index and other balanced approaches can all work. The winner is usually the one a person can continue safely.

Movement: make muscle part of the prescription

Aerobic activity improves fitness and insulin sensitivity. Resistance exercise preserves or builds muscle, which is particularly valuable during weight loss because muscle is a major user of glucose. Walking, cycling, swimming, dancing and gym-based exercise all count. Starting below one’s maximum and progressing steadily is considerably more useful than a heroic Monday followed by a horizontal fortnight.

If using a powerful appetite-suppressing medicine, adequate protein and resistance exercise become even more important to limit loss of lean tissue.

Sleep, stress and eating behaviour

Poor sleep can worsen appetite, insulin sensitivity and blood pressure. PCOS is also associated with a higher risk of obstructive sleep apnoea independent of BMI, so persistent snoring or daytime sleepiness deserves assessment—not merely another alarm clock.

Depression, anxiety, body-image distress and disordered eating are more common in PCOS. They should be recognised and treated. Any weight plan that worsens mental health or disordered eating needs to be reconsidered.

Metformin: the established metabolic workhorse

Metformin reduces the liver’s glucose output and improves the body’s response to insulin. The international guideline recommends considering it in adults with PCOS and a BMI of 25 kg/m² or above for insulin resistance, glucose, lipid and body-measure outcomes. It can also be considered below this BMI, although the evidence is more limited.

It is especially reasonable when there is prediabetes, impaired glucose tolerance, type 2 diabetes risk, a higher-risk ethnic background, or when metabolic concerns coexist with irregular periods.

What metformin can and cannot do

Potential advantages

• long clinical experience and generally low cost;

• improves glucose regulation and may help prevent progression to diabetes in high-risk people;

• may produce modest weight loss or help prevent further gain;

• may improve menstrual regularity in some women; and

• does not usually cause low blood glucose when used alone.

Limitations and side effects

• weight loss is usually modest—metformin is not Mounjaro in a tablet costume;

• nausea, diarrhoea, abdominal discomfort and metallic taste are common initially;

• starting low, increasing gradually and using modified-release preparations can help; and

• long-term use can reduce vitamin B12, so monitoring is sensible when symptoms or additional risk factors are present.

Metformin and an active lifestyle have broadly similar efficacy for several PCOS metabolic outcomes. They can also be combined when that fits the person’s goals and risk.

GLP-1 medicines—and where Mounjaro fits

A naming point first

Medicines such as liraglutide and semaglutide activate the GLP-1 receptor. Tirzepatide, the active drug in Mounjaro, activates both GIP and GLP-1 receptors. It is therefore more accurately described as a dual GIP/GLP-1 receptor agonist, although it is often grouped with “GLP-1 medicines” in everyday conversation.

These gut-hormone pathways act in the brain, pancreas and digestive system. Tirzepatide reduces hunger and food cravings, increases fullness, improves glucose-dependent insulin release, lowers inappropriate glucagon signalling and slows stomach emptying—particularly early in treatment. In plain English, it turns down the biological volume of hunger. It does not remove the need to eat well; it can make doing so much less of a wrestling match.

Is Mounjaro licensed for PCOS?

No. Mounjaro is not licensed as a direct treatment for PCOS.

In the UK, it is licensed for type 2 diabetes and for weight management in adults with:

• a BMI of 30 kg/m² or above; or

• a BMI from 27 to under 30 kg/m² plus at least one weight-related health problem.

Therefore, a woman with PCOS may qualify because she meets the criteria for obesity or overweight with a related health condition, not simply because she has PCOS. NHS availability uses additional service and commissioning criteria and may be narrower than the medicine’s licence.

The 2023 PCOS guideline supports considering anti-obesity medicines, including liraglutide, semaglutide and orlistat, alongside active lifestyle treatment and according to general obesity guidance. Tirzepatide was not named in that guideline because its UK weight-management authorisation arrived later in 2023.

How effective is tirzepatide for weight loss?

Strong evidence in people with obesity—but not specifically PCOS

In the pivotal 72-week SURMOUNT-1 randomised trial of 2,539 adults with obesity, or overweight plus a weight-related complication, without diabetes, average weight loss was approximately:

• 15.0% with tirzepatide 5 mg weekly;

• 19.5% with 10 mg;

• 20.9% with 15 mg; and

• 3.1% with placebo.

About half of participants taking 10 mg and 57% taking 15 mg lost at least 20% of their starting weight. Cardiometabolic measures also improved. These are group averages, not a promise to an individual, and participants received structured lifestyle support.

People with type 2 diabetes generally lose somewhat less weight than people without diabetes, although glucose control can improve substantially.

What evidence do we have in PCOS?

Here the answer requires both optimism and decent brakes.

1. GLP-1 medicines as a class: A 2026 systematic review found 11 randomised trials in PCOS. Adding a GLP-1 receptor agonist reduced BMI by an average of 1.38 kg/m² compared with control, but certainty was low. Evidence was insufficient to establish clear effects on glucose, insulin, hirsutism or menstrual regularity. These studies largely involved older GLP-1 medicines—not tirzepatide.

2. The first substantial tirzepatide real-world PCOS analysis: An August 2026 UK retrospective cohort included 54,114 women prescribed tirzepatide, of whom 4,241 reported PCOS. Weight loss was broadly similar with and without PCOS. Among the 40 women with PCOS who had reached a 10-month measurement, average weight loss was 19.4%, and an estimated 57.7% had lost at least 20%.

That is genuinely encouraging. It also has important limitations: PCOS was self-reported, this was not a randomised trial, follow-up data thinned markedly over time, and only 40 women contributed to the quoted 10-month mean. It tells us that tirzepatide appears to work for weight loss in women who report PCOS; it does not yet prove a direct effect on ovulation, fertility, androgens or long-term PCOS complications.

3. Dedicated trials are now being developed: A registered study is specifically evaluating tirzepatide’s reproductive and metabolic effects in women with PCOS and overweight or obesity. Until robust results arrive, claims that Mounjaro “balances PCOS hormones” or “restores fertility” are ahead of the evidence.

What might improve if weight falls?

Reducing excess adipose tissue can improve insulin sensitivity, glucose, blood pressure, sleep apnoea and fatty liver risk. Some women may also find that ovulation and cycle regularity improve as insulin levels and metabolic health improve.

But these downstream reproductive benefits are possible, not guaranteed, and Mounjaro should not be used as a fertility treatment. Improved ovulation can also mean pregnancy becomes possible unexpectedly—making contraception particularly important.

Mounjaro: advantages, drawbacks and practical cautions

Potential Advantages	Limitations
Among the most effective currently licensed medicines for weight management	Nausea, diarrhoea, constipation, vomiting, reflux and abdominal discomfort are common, especially during dose escalation
Once-weekly injection	Requires gradual titration; the highest dose is not automatically the best dose
Strong glucose-lowering effect in type 2 diabetes	Can cause dehydration; persistent vomiting or inability to drink needs clinical advice
Often reduces hunger and food “noise”	Gallstones can occur, especially with rapid weight loss
May improve waist circumference, blood pressure and other metabolic markers	Pancreatitis is uncommon but serious; persistent severe abdominal pain, especially radiating to the back, requires urgent medical assessment
Low risk of hypoglycaemia when used alone	Hypoglycaemia risk rises when combined with insulin or sulphonylureas, whose doses may need adjustment
Early real-world PCOS weight-loss data are encouraging	Direct PCOS evidence remains limited; long-term reproductive outcomes are unknown
Can be used long term when effective, tolerated and clinically appropriate	Cost and access can be substantial; weight regain is common after stopping

Treatment is normally started at a low dose and increased no faster than every four weeks. Dose escalation is a tolerance tool, not a race. If a lower dose is effective and side effects are troublesome, the pen does not award medals for reaching 15 mg.

People with severe gastroparesis or significant digestive-motility problems need particular caution. A history of pancreatitis, gallbladder disease, diabetic eye disease, other medicines and upcoming anaesthesia should be discussed with the prescriber.

Is it a short course?

Usually, obesity treatment should be viewed as long-term treatment. In SURMOUNT-4, participants first lost an average of 20.9% over 36 weeks. Over the following year, those who continued tirzepatide lost a further 5.5%, while those switched to placebo regained 14.0% from the randomisation point. Continuing treatment preserved at least 80% of the initial loss in 89.5%, compared with 16.6% after switching to placebo.

This is not evidence of addiction. It is evidence that the biology being treated returns when treatment is removed—rather like blood pressure rising when an effective blood-pressure tablet is stopped.

Before starting, it is wise to discuss affordability, supply, side effects, long-term plans and what would happen if treatment had to stop.

Pregnancy and contraception: the section not to skim

Mounjaro must not be used during pregnancy or while trying to conceive. UK regulators also advise against use during breastfeeding. If pregnancy occurs, stop the medicine and contact the prescriber promptly. Anyone planning pregnancy should agree a stopping interval and alternative plan with the clinical team before trying to conceive.

Tirzepatide can reduce the reliability of oral contraceptive pills in women with overweight or obesity, particularly when treatment begins and after a dose increase. UK product information advises adding a barrier method, such as condoms, or changing to a non-oral contraceptive method for:

• four weeks after starting Mounjaro; and

• four weeks after every dose increase.

Vomiting or severe diarrhoea can further reduce pill absorption. This warning is especially relevant in PCOS because improved ovulation may make pregnancy possible even before periods become perfectly regular.

Protecting muscle and nutrition during GLP-1 treatment

Substantial weight loss includes some lean tissue as well as fat. The aim is not merely to make the number on the scale smaller; it is to improve health while preserving strength.

A good treatment plan should include:

• adequate protein distributed through the day;

• resistance exercise two or more times a week where feasible;

• regular nourishing meals rather than surviving on two crackers because appetite has vanished;

• attention to fibre and fluids, especially if constipation develops; and

• review if there is persistent vomiting, dizziness, marked weakness, rapid hair loss or inability to meet nutritional needs.

Other metabolic treatments

Orlistat

Orlistat reduces absorption of dietary fat and can help with weight loss, but it is less potent than modern incretin medicines. Oily stools, urgency and wind with discharge can occur—proof that pharmacology occasionally has the comic timing of a schoolboy. Fat-soluble vitamin status and medicine interactions may require attention.

Inositol

Inositol is widely marketed for PCOS and appears to have limited harms, but preparations vary and the clinical benefits for weight, ovulation and hirsutism remain uncertain. The international guideline could not recommend a specific type, combination or dose because good-quality evidence is lacking. It should not quietly replace proven treatment for diabetes, hypertension or significant dyslipidaemia.

Blood pressure, cholesterol and diabetes medicines

PCOS does not require exotic versions of ordinary cardiovascular care. Persistent hypertension, high cholesterol or type 2 diabetes should be treated according to established guidance, taking pregnancy plans into account. Depending on the problem, this may include antihypertensives, statins or additional glucose-lowering medicines. Statins and several blood-pressure medicines are unsuitable during pregnancy, so contraception and preconception review matter.

Bariatric or metabolic surgery

For severe obesity, especially with type 2 diabetes, sleep apnoea or other major complications, metabolic surgery may be the most effective durable treatment. PCOS guidance recognises possible improvements in weight, diabetes risk, blood pressure, cycles, ovulation and pregnancy rates. Surgery requires specialist assessment, lifelong nutritional follow-up and careful pregnancy timing; fertility can improve rapidly after weight loss.

What if I have “lean PCOS”?

Do not prescribe weight loss to someone who does not need or want it.

Women with PCOS at a lower BMI can still have impaired glucose tolerance, abnormal cholesterol or other metabolic risks, so appropriate screening remains important. Treatment should target what is actually abnormal: fitness, diet quality, sleep, glucose, blood pressure or lipids—not weight loss for its own sake. Metformin may sometimes be considered, but evidence is less certain below a BMI of 25 kg/m². Mounjaro is not an appropriate cosmetic treatment and should only be used within its clinical indications.

A sensible treatment pathway

1. Define the target. Is the priority diabetes prevention, treatment of diabetes, weight, blood pressure, cholesterol, sleep or another problem?

2. Measure the starting point. Review blood pressure, glucose (preferably OGTT where appropriate), lipids, weight trajectory, medicines, family history, sleep, mental health and pregnancy plans.

3. Build sustainable foundations. Choose achievable food, movement, sleep and behavioural changes—with support rather than blame.

4. Add the treatment that matches the target. Metformin for metabolic indications; an evidence-based obesity medicine such as tirzepatide when eligibility, preference and safety align; specific treatment for diabetes, hypertension or dyslipidaemia when present.

5. Review outcomes beyond kilograms. Glucose, waist or clothing fit if useful, blood pressure, lipids, fitness, sleep, side effects, menstrual pattern, quality of life and preservation of strength all matter.

6. Plan for the long term. Decide how treatment will be maintained, what monitoring is needed, and what changes if pregnancy becomes a goal.

Questions to ask before starting Mounjaro

• Do I meet the medical criteria for treatment, and what health outcome are we targeting?

• Could another condition or medicine be contributing to my weight or symptoms?

• What are my pregnancy plans, and is my contraception reliable during dose escalation?

• Do I have digestive-motility problems, gallbladder disease, previous pancreatitis or upcoming surgery?

• How will we protect protein intake, muscle and hydration?

• What result would count as worthwhile—and when will we review it?

• Can I realistically access and continue treatment long term?

• What is our plan if side effects occur or treatment has to stop?

The bottom line

The metabolic side of PCOS deserves active treatment, but not automatic blame.

Lifestyle measures remain the foundation because they improve health even without weight loss. Metformin is a well-established option when insulin resistance, glucose risk or other metabolic concerns are important. For women who meet weight-management criteria, tirzepatide can produce large, clinically meaningful weight loss and improve several drivers of metabolic risk.

The evidence specific to PCOS is moving quickly. Early real-world tirzepatide data are reassuring and impressive for weight loss, but we still need randomised trials to know whether it independently improves androgens, ovulation, fertility and long-term PCOS outcomes. Mounjaro is therefore best viewed as a powerful treatment for obesity and metabolic disease in a woman who also has PCOS—not yet as a proven treatment for every aspect of PCOS.

The best plan is the one that treats your actual risks, respects your priorities, protects pregnancy choices and can be sustained after the initial enthusiasm has stopped doing cartwheels.